Increasing Prescription Drug Competition Act

Cost and committee reports

Official records Congress.gov attaches to H.R. 4692.

• Constitutional authority statementThe sponsor’s statement of where the Constitution gives Congress the power to pass this bill. Statement by Ms. SLOTKIN, as printed in the Congressional Record (Vol. 169, No. 122, July 17, 2023, Pages H3641-H3642):
  To make all Laws which shall be necessary and proper for carrying into Execution the foregoing Powers, and all other Powers vested by this Constitution in the Government of the United States, or in any Department or Officer thereof. The single subject of this legislation is: This bill will restrict pharmacutical companies from abusing their Risk Evaluation and Mitigation Strategy (REMS) program to slow or block generic medications from entering the market.
  Source: Congress.gov, Congressional Record July 17, 2023 ↗

  Evidence

  Field in the Congress.gov record

  constitutionalAuthorityStatementText

  Statement length

  460 characters

  Congress.gov bill record

  H.R. 4692, 118th Congress

  Congress.gov API record

  https://api.congress.gov/v3/bill/118/hr/4692

  Record last updated by Congress.gov

  December 5, 2025

  PORKER copy retrieved

  September 14, 2026

  Stored copy, SHA-256 of the file

  05d22ab3057386331248e4726616a9a8db1134c67566827f9f703edb277415ed

  PORKER shows the statement exactly as printed, with the page markup removed. It is the sponsor’s claim; it is not a legal finding.

Congress.gov’s record for this bill does not list a CBO cost estimate or a committee report (as of December 5, 2025). Not every bill gets one.

From the Congress.gov bill record for H.R. 4692, last updated December 5, 2025. PORKER’s copy was retrieved September 14, 2026 and is refreshed nightly. Open “Evidence” on any line for the record, field and file fingerprint.